home / stock / meobf / meobf short
Short Information | Mesoblast Ltd Ord (OTCMKTS:MEOBF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 26,801 |
Total Actual Volume | 1,453,331 |
Short Trends | |
---|---|
Cover Days | 3 |
Short Days | 17 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 1,340 |
Average Short Percentage | 83.79% |
Is there a MEOBF Short Squeeze or Breakout about to happen?
See the MEOBF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-23-2024 | $0.87 | $0.87 | $0.87 | $0.87 | 100 | 100 | 100% |
05-06-2024 | $0.79 | $0.79 | $0.79 | $0.79 | 100 | 100 | 100% |
04-29-2024 | $0.76 | $0.76 | $0.76 | $0.76 | 105 | 100 | 95.24% |
04-23-2024 | $0.55 | $0.6051 | $0.6051 | $0.55 | 3,000 | 3,000 | 100% |
03-28-2024 | $0.4675 | $0.43 | $0.4675 | $0.43 | 694,185 | 200 | 0.03% |
12-28-2023 | $0.2467 | $0.1667 | $0.2467 | $0.1667 | 10,000 | 5,000 | 50% |
08-24-2023 | $0.3543 | $0.2945 | $0.3543 | $0.2943 | 722,440 | 400 | 0.06% |
08-04-2023 | $0.35 | $0.35 | $0.35 | $0.35 | 2,000 | 2,000 | 100% |
08-02-2023 | $0.85 | $0.85 | $0.85 | $0.85 | 1,000 | 1,000 | 100% |
08-01-2023 | $0.7462 | $0.7615 | $0.7615 | $0.7462 | 3,000 | 3,000 | 100% |
07-26-2023 | $0.8249 | $0.8249 | $0.8249 | $0.8249 | 100 | 100 | 100% |
07-24-2023 | $0.85 | $0.8722 | $0.8722 | $0.85 | 3,000 | 3,000 | 100% |
07-17-2023 | $0.9878 | $1 | $1 | $0.9874 | 2,100 | 2,100 | 100% |
07-13-2023 | $0.92 | $0.9259 | $0.9259 | $0.92 | 2,000 | 2,000 | 100% |
06-22-2023 | $0.833 | $0.833 | $0.833 | $0.833 | 1,000 | 1,000 | 100% |
06-05-2023 | $0.9 | $0.9 | $0.9 | $0.9 | 200 | 200 | 100% |
05-17-2023 | $0.7825 | $0.7825 | $0.7825 | $0.7825 | 100 | 100 | 100% |
04-27-2023 | $0.61 | $0.61 | $0.61 | $0.61 | 1,000 | 1,000 | 100% |
03-08-2023 | $0.7073 | $0.7389 | $0.7521 | $0.7073 | 7,900 | 2,400 | 30.38% |
12-27-2022 | $0 | $0.5749 | $0 | $0 | 1 | 1 | 100% |
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for...
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product...
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today it has resubmitted its BLA for approval of Ryoncil ® (remestemcel-L) in the treatment of children with SR-aGVHD....